CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate

CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate

<b>Background</b>: Glatiramer acetate (GA) is an effective treatment for the earliest stages of multiple sclerosis (MS)&#8212;clinically isolated syndrome (CIS) or clinically definite MS (CDMS). Objective: This study aims to determine the differences in the lymphocyte population (at...

Full description

Bibliographic Details
Main Authors: Martin Vališ, Lukáš Sobíšek, Oldřich Vyšata, Blanka Klímová, Ctirad Andrýs, Doris Vokurková, Jiří Masopust, Zbyšek Pavelek
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Cells
Subjects:
multiple sclerosis
glatiramer acetate
biomarker
CD4+/CD45RO+
patients
disease progression
Online Access:https://www.mdpi.com/2073-4409/8/5/456

Internet

https://www.mdpi.com/2073-4409/8/5/456

Similar Items